BCL2L11 and melanoma: A panel consisted of 4 markers (ING4-Cul1-BRG1-Bim) achieved 94.3% sensitivity and attained 81.8% specificity for discrimination of melanoma from dysplastic nevi, and AUC is 84.3%, higher than 71.9% for 2-markers (ING4-Cul1) and 76.9% for 3-markers (ING4-Cul1-BRG1) (Figure 2).